A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults

CompletedOBSERVATIONAL

Enrollment

124,879

Participants

Timeline

Start Date

September 10, 2021

Primary Completion Date

February 4, 2022

Study Completion Date

March 21, 2022

Conditions

SARS-CoV-2

Trial Locations (1)

Aetion Inc., New York

All Listed Sponsors

lead

ModernaTX, Inc.

INDUSTRY

NCT05366322 - A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults | Biotech Hunter | Biotech Hunter